TORONTO, Sept. 1 /CNW/ - Patheon (TSX:PTI), a leading global provider of
drug development and manufacturing services to the international
pharmaceutical industry, announces its results for the third quarter ended
July 31, 2005. (All amounts are in U.S. dollars unless otherwise indicated.)
Third Quarter Results
- Revenues increased 53% to $178.4 million;
- Internal revenue growth was 19%; strategic growth was $39.4 million;
- EBITDA increased 134% to $25.8 million; the EBITDA margin was 14.5%
versus 9.4% a year ago (11.3% before U.K. repositioning costs);
- Cash provided from operations increased 99% to $18.1 million;
- Net earnings increased 74% to $3.5 million; basic earnings per share
were 3.5 cents versus 3.9 cents a year ago after U.K. repositioning
costs.
Year-to-Date Results
- Revenues increased 49% to $516.4 million;
- Internal revenue growth was 17%; strategic growth was $108.4 million;
- EBITDA rose 107% to $71.8 million; the EBITDA margin was 13.9% versus
10.0% a year ago (10.6% before U.K. repositioning costs);
- Cash provided from operations increased 85% to $54.9 million;
- Net earnings increased 72% to $13.2 million; basic earnings per share
rose to 15.6 cents from 14.9 cents a year ago after U.K. repositioning
costs.
"We were disappointed with our third quarter results because of earnings
that were lower than we anticipated," said Mr. Robert C. Tedford, Chief
Executive Officer of Patheon Inc. "At the same time, we saw a number of
positive factors in the quarter which indicate continuing progress toward the
achievement of our long-term strategy. With internal growth of 19% and the
added contribution from the MOVA operations, our consolidated revenues
increased by 53% and EBITDA by 134%. Cash flow from operations doubled and the
ratio of long-term debt to shareholders' equity - a key balance sheet metric -
improved over the last quarter. These results, however, were not reflected in
earnings per share because of lower margins and profitability quarter over
quarter at our MOVA operations."
In the third quarter, consolidated revenues increased by $61.6 million
over the previous year, reflecting internal growth of $22.2 million and
strategic growth of $39.4 million related to the MOVA operations acquired on
December 23, 2004. Revenues from prescription (Rx) manufacturing and PDS
services grew by $57.0 million and $5.0 million, respectively, offset by a
slight reduction in over-the-counter (OTC) revenues. Revenues from North
American and European operations increased by $47.1 million and $14.5 million,
respectively. For the three months ended July 31, 2005, Rx activities
accounted for 74% of revenues, PDS for 12% and OTC for 14%. North American and
European operations accounted for 68% and 32% of revenues, respectively.
"Internal growth during the third quarter was 19% on a year-over-year
basis," commented Mr. Tedford. "PDS revenues increased by 30% over a year ago,
with a strong performance in North America as well as in Europe. This reflects
both growing demand and increased recognition in the industry of the breadth
of Patheon's pharmaceutical development expertise and capabilities. Internal
growth was also driven by a 26% increase in Rx commercial revenues, reflecting
a significant contribution from Europe, particularly the Swindon and Ferentino
operations, as well as the success of new product launches and volume
increases at the Toronto high-potency site in North America.
"Strategic revenues of $39.4 million from the MOVA operations were
clearly disappointing," continued Mr. Tedford. "Production volumes in the
third quarter continued to be challenged by the shortage of a client-supplied
active pharmaceutical ingredient ("API") - a situation that has now improved
and allows a return to higher production volumes in the fourth quarter and
beyond. In addition, volume adjustments by our client for a significant
product launched in 2004 continued to take place in the third quarter, with
the result that revenues from this product were substantially lower than
anticipated."
EBITDA amounted to $25.8 million, an increase of $14.8 million or 134%
over a year ago. The EBITDA margin in the quarter was 14.5% compared with 9.4%
a year earlier, or 11.3% before U.K. repositioning costs. The expansion in
EBITDA margin was largely attributable to higher Rx volumes and improved
product mix both in North America and in Europe. In North America, Rx revenues
were driven by new product launches and volume increases at the Toronto
high-potency site, and in Europe by the significant improvement in operating
performance at Swindon and the start-up of new sterile capacity in Ferentino.
While in prior quarters of 2005, MOVA had higher EBITDA margins than other
operations in the Company's network, MOVA margins in the third quarter were
comparable with the other operations due to reduced capacity utilization.
Net earnings increased by 74% to $3.5 million in the third quarter.
However, earnings per share of 3.5 cents were lower than the 3.9 cents
achieved a year earlier. This was attributable to lower profitability at the
MOVA sites, higher non-cash charges and acquisition-related expenses as well
as an 80% increase in the average number of shares outstanding year over year
due to shares issued in connection with the MOVA acquisition.
Cash provided from operations almost doubled to $18.1 million in the
third quarter and increased to $54.9 million for the year to date, reflecting
contributions from both existing and MOVA operations. During the quarter, the
Company generated free cash flow of $8.4 million. Cash and cash equivalents at
July 31, 2005 were $23.8 million including restricted cash at MOVA of $4.1
million, compared with $7.6 million at the end of the 2004 fiscal year.
The MOVA agreement provided for two earn-out arrangements relating to
MOVA's operating results for two specific periods. The maximum amounts for the
first and second earn-outs were $65 million and $26 million, respectively. The
first earn-out was paid in full on June 23, 2005. However, based on MOVA's
operating results to June 30, 2005, the second earn-out was not payable. The
funds that had been held in escrow were released and applied to reduce debt in
the third quarter.
At July 31, 2005, the Company's ratio of consolidated interest-bearing
long-term debt to shareholders' equity was 58% compared with 65% in the second
quarter and 56% at year end.
During the third quarter, Mr. Clive V. Bennett was appointed to the
position of President, Patheon U.S.A., and President and Chief Operating
Officer of MOVA Pharmaceutical Corporation, reporting to Nick DiPietro,
President and Chief Operating Officer of Patheon Inc. In accordance with the
transition plans announced at the time of the MOVA acquisition in December
2004, Mr. Joaquin Viso has resigned as President and Chief Executive Officer
of MOVA to become MOVA's non-executive Chairman. Mr. Viso also continues to
serve as a Director of Patheon Inc.
Outlook
"Looking ahead to the end of 2005 and beyond, we continue to hone our
business fundamentals and to capitalize on business opportunities that will
further enhance our global positioning in outsourced pharmaceutical
manufacturing," said Mr. Tedford.
"The growing number of projects in our PDS pipeline speaks to the
positive R&D spending trends and demand in both North America and Europe for
high-quality drug development services," commented Mr. Tedford. "At quarter
end, we had a total of 137 projects in our facilities, seven of which were at
the NDA stage. This compared with 109 projects just one year ago.
"In North America, the demand for specialized Rx services, such as our
high-potency capacity in Canada and our sustained-release capacity at
Cincinnati, continues to grow," added Mr. Tedford. "However, we continue to be
challenged to grow our OTC business. This segment of the pharmaceutical market
is highly competitive, price-sensitive and subject to volatility in consumer
demand.
"We are encouraged by the all-round strong performance of our European
sites in the third quarter, both for our Rx manufacturing and PDS services,"
added Mr. Tedford. "In addition to signing a number of contracts for our
sterile and cephalosporin capabilities, we have signed an important contract
to manufacture a new cephalosporin product for our Swindon site and two multi-
product contracts that will benefit our Italian and French sites. As reported
last quarter, we continue to be on track for profitability at Swindon in 2006.
"At MOVA, we have been faced with challenges that have impacted operating
results," commented Mr. Tedford. "We are pleased that the API shortage for a
significant product has improved, allowing higher production volumes to
resume. With regard to the new product launched in 2004, we expect that client
requirements for the product will recover during the first part of fiscal
2006. Both of these are large-volume products and, based on discussions with
our clients, we anticipate that market demand for these products will remain
strong.
"We are disappointed that as a result of issues with two key products the
MOVA operations will not be accretive to earnings per share in 2005 as
originally expected," said Mr. Tedford. "We have identified a number of new
opportunities to fill additional capacity at the MOVA sites created by
changing client requirements for currently marketed products as well as by
anticipated volume declines of a product going off-patent in 2006. Based on
these new opportunities combined with the strategic benefits - additional Rx
manufacturing capabilities and expertise in a tax-advantaged location - that
MOVA has brought to the organization, we remain confident that MOVA represents
a significant opportunity for accretive growth."
This management's discussion and analysis of financial condition and
results of operations contains forward-looking statements with respect to the
Company, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular the Company's
clients), the impact of changes in pharmaceutical development and
manufacturing regulations and general economic and market factors (including
inflation and changes in laws) and other factors discussed in materials filed
with applicable securities regulatory authorities from time to time.
All amounts reported are in U.S. dollars unless otherwise indicated.
Patheon Inc. will host a webcast conference call with financial analysts
on its third quarter results on Friday, September 2, 2005 at 10:00 a.m. (EDT).
Representing Patheon on the call will be: Robert Tedford, Chief Executive
Officer and Nick DiPietro, President and Chief Operating Officer. Interested
parties are invited to access the call live, in listen-only mode, via
telephone, at (416) 640-4127 or toll-free, at 1-800-814-4862. (Please call
between five and fifteen minutes in advance.) A live audio webcast, with a
slide presentation, will be available on www.patheon.com. An archived version
of the Q3 webcast will be available on www.patheon.com for three months.
ABOUT PATHEON
Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical
Corporation, acquired in December 2004, Patheon operates a network of 14
facilities in the United States, Canada and Europe, employing more than 5,900
people and serving a client base of 180 pharmaceutical and biotechnology
companies.
<<
Consolidated Statements of Earnings
(unaudited)
Three months Nine months
ended July 31, ended July 31,
% %
2005 2004 change 2005 2004 change
-------------------------------------------------------------------------
(in thousands of
U.S. dollars, except
per share amounts) $ $ $ $
-------------------------------------------------------------------------
Revenues 178,390 116,840 52.7% 516,425 347,438 48.6%
Operating expenses 152,198 103,230 47.4% 443,457 309,748 43.2%
Repositioning expenses
(note 13) - 2,142 - 2,142
Stock-based
compensation 366 433 -15.5% 1,209 928 30.3%
------------------------- -------------------------
Earnings before
depreciation and
amortization, interest
and income taxes 25,826 11,035 134.0% 71,759 34,620 107.3%
------------------------- -------------------------
(as a % of revenues) 14.5% 9.4% 13.9% 10.0%
Depreciation 8,868 5,743 54.4% 25,545 16,814 51.9%
Amortization of
intangible assets
(note 3) 3,221 - 7,745 -
Interest 4,783 1,404 240.7% 11,797 3,811 209.6%
Amortization of
deferred financing
costs (note 11) 1,374 - 5,531 -
------------------------- -------------------------
Earnings before income
taxes 7,580 3,888 95.0% 21,141 13,995 51.1%
Provision for income
taxes 4,125 1,898 117.3% 7,899 6,314 25.1%
------------------------- -------------------------
Net earnings for the
period 3,455 1,990 73.6% 13,242 7,681 72.4%
------------------------- -------------------------
------------------------- -------------------------
(as a % of revenues) 1.9% 1.7% 2.6% 2.2%
Earnings per share
(note 2)
3.5 3.9 15.6 14.9
Basic cents cents -10.3% cents cents 4.7%
------------------------- -------------------------
3.4 3.9 15.5 14.8
Diluted cents cents -12.8% cents cents 4.7%
------------------------- -------------------------
Average number of
shares outstanding
during period:
Basic (in thousands) 92,846 51,515 80.2% 84,799 51,509 64.6%
------------------------- -------------------------
Diluted (in
thousands) 93,242 51,973 79.4% 85,227 52,007 63.9%
------------------------- -------------------------
see accompanying notes
Consolidated Statements of Retained Earnings
(unaudited)
Nine months ended July 31,
2005 2004
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $
-------------------------------------------------------------------------
Retained earnings, beginning of the year 76,629 65,951
Net earnings for the period 13,242 7,681
-------------------------
Retained earnings, end of period 89,871 73,632
-------------------------
-------------------------
see accompanying notes
Consolidated Balance Sheets
(unaudited)
As at As at
July 31, October 31,
2005 2004
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $
-------------------------------------------------------------------------
Assets
Current
Cash and cash equivalents (note 5) 18,966 7,626
Certificate of deposit (note 5) 4,824 -
Accounts receivable 129,338 95,305
Inventories 76,421 58,763
Income taxes receivable - 1,029
Prepaid expenses and other 5,771 2,768
-----------------------------
Total current assets 235,320 165,491
-----------------------------
Capital assets, net 475,407 331,725
Future tax assets 19,739 15,800
Goodwill (note 3) 162,940 2,837
Intangible assets, net (note 3) 109,573 -
Deferred pre-operating and financing costs 13,437 5,498
Investment 1,226 1,232
-----------------------------
1,017,642 522,583
-----------------------------
-----------------------------
Liabilities and Shareholders' equity
Current
Bank indebtedness 13,041 21,454
Accounts payable and accrued
liabilities 118,183 105,567
Income taxes payable 2,652 -
Current portion of long-term debt
(note 10) 109,717 11,146
-----------------------------
Total current liabilities 243,593 138,167
-----------------------------
Long-term debt (note 10) 188,094 113,116
Other long-term liabilities 22,334 21,660
Deferred revenues (notes 3, 12) 14,787 -
Future tax liabilities 33,654 28,242
-----------------------------
Total liabilities 502,462 301,185
-----------------------------
Shareholders' equity
Share capital (note 4) 400,594 118,954
Contributed surplus 2,582 1,373
Retained earnings 89,871 76,629
Cumulative translation adjustment 22,133 24,442
-----------------------------
Total shareholders' equity 515,180 221,398
-----------------------------
1,017,642 522,583
-----------------------------
-----------------------------
see accompanying notes
Consolidated Statements of Cash Flows
(unaudited)
Three months Nine months
ended July 31, ended July 31,
2005 2004 2005 2004
-------------------------------------------------------------------------
(in thousands of U.S. dollars,
except per share amounts) $ $ $ $
-------------------------------------------------------------------------
Cash provided by (used in):
Operating activities
Net earnings for the period 3,455 1,990 13,242 7,681
Add (deduct) charges to operations
not requiring a current cash
payment
Depreciation and amortization 13,463 5,743 38,821 16,814
Employee future benefits 586 664 1,395 1,807
Future income taxes 389 (469) 671 1,655
Equipment write-down (note 13) - 750 - 750
Stock-based compensation 366 433 1,209 928
Amortization of deferred
revenues (280) - (618) -
Other 165 - 165 -
---------------------------------------
Cash provided from operations 18,144 9,111 54,885 29,635
Net change in non-cash working
capital balances related to
operations 2,831 (8,370) (10,314) (9,831)
---------------------------------------
Cash provided by operating
activities 20,975 741 44,571 19,804
---------------------------------------
Investing activities
Acquisition of MOVA Pharmaceutical
Corporation (note 3) (69,976) - (214,521) -
Additions to capital assets
- sustaining (4,998) (2,690) (9,328) (8,041)
- project-related (7,557) (9,454) (29,553) (34,880)
Decrease in escrow cash related
to MOVA acquisition (note 3) 87,825 - - -
Redemption of certificate of
deposit 391 - 391 -
Increase in deferred pre-
operating and financing costs (411) (1,512) (12,000) (1,512)
---------------------------------------
Cash provided by (used in)
investing activities 5,274 (13,656) (265,011) (44,433)
---------------------------------------
Financing activities
Increase (decrease) in bank
indebtedness (5,888) (729) (7,731) 3,719
Increase in term loans 64,179 47,033 295,090 61,303
Repayment of long-term debt and
other long-term liabilities (90,011) (40,421) (249,171) (45,988)
Increase in deferred revenues
(note 12) 8,271 - 8,271 -
Proceeds on issue of common
shares before costs - 22 199,241 22
Share issue costs - - (8,947) -
---------------------------------------
Cash provided by (used in)
financing activities (23,449) 5,905 236,753 19,056
---------------------------------------
Effect of exchange rate changes
on cash and cash equivalents (12) (378) (4,973) (181)
---------------------------------------
Net increase (decrease) in cash
and cash equivalents during
the period 2,788 (7,388) 11,340 (5,754)
Cash and cash equivalents,
beginning of period 16,178 10,804 7,626 9,170
---------------------------------------
Cash and cash equivalents,
end of period 18,966 3,416 18,966 3,416
---------------------------------------
---------------------------------------
see accompanying notes
Patheon Inc.
Notes to Unaudited Consolidated Financial Statements
for the Nine Months Ended July 31, 2005
(Dollar information in tabular form is expressed
in thousands of U.S. dollars)
1. Accounting policies
The accompanying consolidated financial statements have been prepared by
the Company in accordance with Canadian generally accepted accounting
principles on a basis consistent with those followed in the most recent
audited financial statements. These consolidated financial statements do
not include all the information and footnotes required by generally
accepted accounting principles for annual financial statements and
therefore should be read in conjunction with the audited consolidated
financial statements and notes included in the Company's Annual Report
for the year ended October 31, 2004.
2. Earnings per share
The following is a reconciliation of the weighted average number of basic
and diluted shares:
Three months ended July 31,
2005 2004
-------------------------------------------------------------------------
Weighted average number of common shares
outstanding 92,845,688 51,514,518
Effect of dilutive stock options 396,674 458,150
-------------------------------------------------------------------------
Weighted average number of common shares
outstanding - diluted 93,242,362 51,972,668
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Nine months ended July 31,
2005 2004
-------------------------------------------------------------------------
Weighted average number of common shares
outstanding 84,799,487 51,508,742
Effect of dilutive stock options 427,312 498,195
-------------------------------------------------------------------------
Weighted average number of common shares
outstanding - diluted 85,226,799 52,006,937
-------------------------------------------------------------------------
-------------------------------------------------------------------------
3. Acquisition of MOVA Pharmaceutical Corporation
On December 23, 2004, the Company completed the acquisition of
MOVA Pharmaceutical Corporation and MOVA Investments, Inc. (collectively
"MOVA"), a leading U.S. prescription pharmaceutical contract manufacturer
located in Puerto Rico, U.S.A.
The purchase price for the shares of MOVA was based on an enterprise
value for MOVA at closing of $350,000,000. The Company issued 12,684,866
common shares to the shareholders of MOVA in satisfaction of $81,500,000
of the purchase price. The Company assumed approximately $133,300,000 in
debt and related costs, and paid $135,200,000 in cash at closing.
The agreement also provided for two earn-out arrangements relating to
MOVA's operating results for two specific periods. The maximum amounts
for the first and second earn-outs were $65 million and $26 million,
respectively. The Company placed into escrow $87.8 million to support
potential payments under the earn-out arrangements. An agreement was
reached with the former MOVA shareholders to pay the full amount of the
first earn-out arrangement and $65 million was disbursed from escrow on
June 23, 2005. It was determined that no amount was payable under the
second earn-out and the remaining funds held in escrow were released to
the Company and applied to reduce debt.
The acquisition has been accounted for using the purchase method and the
accompanying consolidated financial statements include the results of
operations from the date of purchase. The purchase price was allocated in
the accounts based on the estimated fair value of the assets acquired as
follows:
--------------
$
--------------
Current assets 62,305
Capital assets 142,001
Other long term assets 1,719
Intangible assets 116,274
Goodwill 158,875
Current liabilities (33,887)
Deferred revenues (7,096)
Future tax liabilities (4,041)
---------------
Net assets acquired before assumed debt 436,150
Less: debt assumed (133,333)
---------------
Net assets acquired 302,817
---------------
---------------
Intangible assets, which represent the value assigned to client
contracts, are being amortized on a straight-line basis over nine years.
The purchase price and related allocations for this acquisition are
preliminary. Adjustments to the purchase price and related preliminary
allocations may occur as a result of obtaining more information regarding
asset valuations, liabilities assumed, purchase price adjustments
pursuant to the purchase agreement and revisions of preliminary estimates
of fair value made at the date of purchase.
The purchase price consideration was as follows:
---------------
$
---------------
Cash consideration 211,237
Transaction costs 3,284
---------------
Total cash consideration 214,521
Value of 12,684,866 common shares issued to shareholders
of MOVA 88,296
---------------
Total consideration 302,817
---------------
---------------
In accordance with generally accepted accounting principles, the value of
the 12,684,866 common shares was determined based on the average market
price of the Company's common shares for the two trading days prior to
the announcement of the transaction and the two trading days following
the announcement.
4. Share capital
The following table summarizes information on share capital and related
matters at July 31, 2005:
Outstanding Exercisable
Common shares 92,845,688
Common share stock options 3,922,109 3,173,256
On December 23, 2004, the Company completed a public offering of
26,000,000 common shares for gross proceeds of approximately
$181.0 million (net proceeds of $172.7 million after offering costs).
The Company also on December 23, 2004, issued 12,684,866 common shares to
the shareholders of MOVA in satisfaction of $81.5 million of the purchase
price of the acquisition.
On January 11, 2005, the underwriters of the public offering on
December 23, 2004, exercised the over-allotment option granted to
purchase an additional 2,600,000 common shares for gross proceeds of
approximately $18.3 million (net proceeds of $17.5 million after offering
costs).
5. Cash and cash equivalents, Certificate of deposit
The Certificate of deposit of $4,824,000 and $4,086,000 of the amount
reported as cash and cash equivalents are restricted cash and are held in
support of certain debt agreements of MOVA.
6. Segmented information
The Company is organized and managed as a single business segment, being
the provider of commercial manufacturing and pharmaceutical development
services.
North American and European operations consist of:
Three months ended July 31, 2005
---------------------------------------
Canada USA Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues
Canada 8,282 272 255 8,809
USA 39,086 63,457 3,106 105,649
Europe 10,281 41 52,165 62,487
Other geographic areas 449 65 931 1,445
-------------------------------------------------------------------------
Total revenues 58,098 63,835 56,457 178,390
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Capital assets 115,701 178,914 180,792 475,407
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Goodwill 2,823 160,117 - 162,940
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Three months ended July 31, 2004
---------------------------------------
Canada USA Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues
Canada 6,327 469 120 6,916
USA 28,426 28,118 2,578 59,122
Europe 10,128 723 38,433 49,284
Other geographic areas 571 68 879 1,518
-------------------------------------------------------------------------
Total revenues 45,452 29,378 42,010 116,840
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Capital assets 102,035 31,130 165,991 299,156
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Goodwill 2,599 - - 2,599
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Nine months ended July 31, 2005
---------------------------------------
Canada USA Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues
Canada 20,727 818 1,409 22,954
USA 124,158 185,083 7,458 316,699
Europe 31,581 344 139,892 171,817
Other geographic areas 2,966 284 1,705 4,955
-------------------------------------------------------------------------
Total revenues 179,432 186,529 150,464 516,425
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Nine months ended July 31, 2004
---------------------------------------
Canada USA Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues
Canada 19,715 1,411 297 21,423
USA 80,664 84,527 3,892 169,083
Europe 27,483 1,996 123,282 152,761
Other geographic areas 1,973 370 1,828 4,171
-------------------------------------------------------------------------
Total revenues 129,835 88,304 129,299 347,438
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Revenue is attributed to countries based on the location of the client's
billing address and capital assets and goodwill are based in the country
in which they are located.
Revenue information by service activity is as follows:
Three months ended July 31,
---------------------------------------
2005 2004
$ $
-------------------------------------------------------------------------
Commercial manufacturing
- prescription 131,463 74% 74,442 64%
Commercial manufacturing
- over-the-counter 25,547 14% 25,995 22%
Development services 21,380 12% 16,403 14%
-------------------------------------------------------------------------
178,390 100% 116,840 100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Nine months ended July 31,
---------------------------------------
2005 2004
$ $
-------------------------------------------------------------------------
Commercial manufacturing
- prescription 370,417 72% 225,861 65%
Commercial manufacturing
- over-the-counter 81,478 16% 74,518 21%
Development services 64,530 12% 47,059 14%
-------------------------------------------------------------------------
516,425 100% 347,438 100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
7. Stock-based compensation
The Company has an incentive stock option plan. Persons eligible to
participate in the plan are directors, officers, and key employees of
Patheon and its subsidiaries or any other person engaged to provide
ongoing management or consulting services to Patheon. The plan provides
that the maximum number of shares that may be issued under the plan is
7.5% of the issued and outstanding common shares of the Company at any
point in time. At July 31, 2005, the total number of common shares listed
on the Toronto Stock Exchange (the "TSX") as available for issuance under
the plan was 6,963,427, of which 3,922,109 were reserved for options
granted and outstanding under the plan. The exercise price of common
shares subject to an option is determined at the time of grant and the
price cannot be less than the weighted average market price of the common
shares of Patheon on the TSX during the two trading days immediately
preceding the grant date. Options generally expire 10 years after the
grant date and are also subject to early expiry in the event of death,
resignation, dismissal or retirement of an optionee. Options generally
vest over three years, one-third on each of the first, second and third
anniversary of the grant date.
Stock options granted prior to November 1, 2003 are accounted for using
the intrinsic value method, which does not give rise to compensation
expense. Had these stock options been accounted for at fair value, the
impact on pro-forma net earnings and earnings per share would have been:
Three months Nine months
ended July 31, ended July 31,
2005 2004 2005 2004
---------------------------------------
$ $ $ $
---------------------------------------
Net earnings as reported 3,455 1,990 13,242 7,681
Pro-forma adjustments for the fair
value of stock options granted
prior to November 1, 2003 (27) (84) (125) (786)
---------------------------------------
Pro-forma net earnings 3,428 1,906 13,117 6,895
---------------------------------------
---------------------------------------
Pro-forma earnings per share:
Basic 3.5 3.7 15.5 13.4
cents cents cents cents
Diluted 3.5 3.7 15.4 13.3
cents cents cents cents
The fair value of stock options is estimated at the date of the grant.
The weighted average fair value of the 35,000 options granted for the
three months ended July 31, 2005 was $3.65. The weighted average fair
value of stock options granted for the nine months ended July 31, 2005
was $3.00. The weighted average fair value of stock options granted for
the comparable nine-month period in 2004 was $3.94. For the three months
ended July 31, 2005, 2,566 options were forfeited. The fair value of
stock options is estimated at the date of grant using the Black-Scholes
option pricing model with the following assumptions:
Risk free interest rate 3.5%
Expected volatility 46%
Expected weighted average life of the options 5 years
Expected dividend yield 0%
8. Other information
Cumulative translation adjustment
The cumulative translation adjustment amount will be impacted by
fluctuations in the value of the U.S. dollar relative to the
Canadian dollar, the euro and the British sterling.
Unrealized translation adjustments, which arise on the translation to
U.S. dollars of the Company's assets and liabilities, resulted in a net
unrealized currency translation gain of $4,187,000 for the three months
ended July 31, 2005 (2004 - unrealized currency translation gain of
$566,000). For the nine months ended July 31, 2005, the unrealized
currency translation loss is $2,309,000 (2004 - unrealized currency
translation gain of $4,385,000).
The net unrealized gain in the quarter of $4,187,000 is attributable to
the strengthening of the U.S. dollar against the euro, and the
British sterling as measured at July 31, 2005 and April 30, 2005, offset
in part by a weakening of the U.S. dollar against the Canadian dollar.
On a year-to-date basis, the net unrealized loss of $2,309,000 is
attributable to the strengthening of the U.S. dollar against the
Canadian dollar, the euro and the British sterling, as measured at
July 31, 2005 and October 31, 2004.
Foreign exchange
During the three months ended July 31, 2005, the foreign exchange loss
was $633,000 (2004 loss - $379,000). For the nine months ended July 31,
2005, the foreign exchange gain was $2,744,000 (2004 gain - $638,000).
9. Financial instruments
The Company utilizes financial instruments to manage the risk associated
with fluctuations in foreign exchange rates. The Company has entered into
foreign exchange expandable forward contracts with an aggregate amount of
between US$14,000,000 and US$21,000,000 as at July 31, 2005. These
contracts mature at the latest on December 31, 2005 at exchange rates
varying between 1.2360 and 1.2665 Canadian. The Company formally
documents all relationships between hedging instruments and hedged items,
as well as its risk management objective and strategy for undertaking
various hedge transactions. The mark-to-market value of these financial
instruments as at July 31, 2005 was an unrealized gain of US$265,000.
10. Long-term debt
On December 23, 2004 the Company completed a financing agreement for a
new $169,000,000 committed facility, comprising a three-year revolving
credit facility of up to $55,000,000 and a 12-month bridge facility of
$114,000,000. This bridge facility is intended to be refinanced by a term
loan within 12 months of the completion date. At the signing of the
financing agreement, $116,000,000 was drawn under these facilities in
partial payment of the cash portion of the purchase price of MOVA and
related transaction costs, and to refinance substantially all of the
Company's existing North American debt of approximately $63,000,000. At
July 31, 2005, the amount drawn under this bridge facility was reduced to
$81,500,000. Until the bridge facility is refinanced, the amount
outstanding is shown as a current liability.
Certain of the loan agreements which were assumed by the Company on
closing of the acquisition of MOVA Pharmaceutical Corporation require
MOVA to maintain certain financial covenants, as measured quarterly on a
calendar-year basis. As of December 31, 2004 and June 30, 2005, MOVA's
compliance reporting dates, MOVA was not in compliance with certain of
the financial covenants. The lending institutions have waived their
rights under the terms of the loan agreements for the non-compliance of
these covenants for a period of time up to November 1, 2006 and any
cross-default provisions of the $169,000,000 credit facility, referred to
above, have also been remedied. Therefore, no change has been made to
assumptions on long-term debt as presented in the accompanying
balance sheet.
11. Amortization of deferred financing costs
Amortization of deferred financing costs in the first nine months of 2005
was $5.5 million. No amounts were recorded for the same period in the
prior year. Of the increase, $2.0 million was recorded in the first
quarter of 2005 and is of a non-recurring nature. The amortization in the
third quarter of 2005 does not include amounts of a non-recurring nature.
12. Deferred revenues
During the third quarter 2005, the Company entered into a Letter of
Intent with a client for the manufacturing of a lyophilized,
cephalosporin product at its Swindon site. In accordance with the terms
of the Letter of Intent, the client contributed $8.3 million
(euros 7.0 million) in the third quarter towards the capital cost of a
new cGMP plant at the Swindon site to accommodate the manufacturing of
the new client volumes. The contribution by the client has been recorded
as deferred revenues and will be recognized as income over the term of
the manufacturing services agreement, commencing in the 2007 fiscal year
through 2010.
13. Repositioning expenses
For the three months and nine months ended July 31, 2004, the Company
recorded expenses related to the repositioning plan for its U.K.
operations designed to reduce operating losses. No amount was recorded
for the three months and nine months ended July 31, 2005, as the
repositioning plan was completed by October 31, 2004.
14. Comparative amounts
Certain of the comparative amounts have been reclassified to conform to
the current year presentation.
Patheon Inc.
Management's Discussion and Analysis of Financial Condition and
Results of Operations
The following is a discussion of financial condition and results of
operations of Patheon Inc. ("Patheon" or "the Company") for the three-month
and nine-month periods ended July 31, 2005 and 2004 and should be read in
conjunction with the Company's consolidated financial statements and related
notes contained in this interim report. This MD&A is dated as of September 1,
2005.
The purpose of this 2005 third quarter report is to provide an update to
the information contained in the Management's Discussion and Analysis (MD&A)
section of Patheon's 2004 Annual Report, which contains a more comprehensive
discussion of Patheon's strategy, capabilities to deliver results, risks and
key performance indicators. Management assumes that the reader of this
document has access to the MD&A section of Patheon's 2004 Annual Report, the
first report for which the Company adopted the latest MD&A reporting
requirements. This document and other information can be downloaded in
portable document format (PDF) from the Company's web site at www.patheon.com
or from the SEDAR web site for Canadian regulatory filings at www.sedar.com.
To request a printed copy, the reader may also contact Patheon's transfer
agent, Computershare Trust Company of Canada, at 1-800- 564-6253 or via email
at service(at)computershare.com, or Patheon at www.patheon.com.
Use of Non-GAAP Financial Measures
Except as otherwise indicated, references in this MD&A to "EBITDA" are to
earnings before depreciation and amortization, interest and income taxes. Free
cash flow is defined as cash provided by operating activities in excess of
additions to capital assets in the period. "EBITDA margin" is EBITDA divided
by revenues. EBITDA and EBITDA margin are measures of earnings or earnings
margin not recognized by generally accepted accounting principles in Canada
("Canadian GAAP"). Free cash flow is a measure of cash flows not recognized by
generally accepted accounting principles in Canada. Since each of these
measures is a non-GAAP measure that does not have a standardized meaning, it
may not be comparable to similar measures presented by other issuers.
Prospective investors are cautioned that these, and other non-GAAP measures
should not be construed as alternatives to net income determined in accordance
with Canadian GAAP as indicators of performance or to cash flows from
operating, investing and financing activities as measures of liquidity and
cash flows. The Company has included these measures because it believes that
this information is used by certain investors to assess financial performance.
Overview of Patheon
Patheon is focused exclusively on providing commercial manufacturing and
pharmaceutical development services to pharmaceutical companies, biotechnology
companies and specialty pharmaceutical companies located primarily in North
America, Europe and Japan. Patheon serves its international clientele from its
operating facilities in North America and Europe.
Patheon's commercial manufacturing activities relate primarily to
prescription ("Rx") and over-the-counter ("OTC") products in solid, semi-
solid and liquid dosage forms and the manufacture of Rx products in sterile
dosage forms. Conventional dosage forms include compressed tablets, hard-
shell gelatin capsules, powders, ointments, creams, gels, syrups, suspensions,
solutions and suppositories. Sterile dosage forms include aseptically filled
liquids or terminally sterilized liquids filled in ampoules, vials, bottles or
pre-filled syringes. Sterile lyophilized products are also manufactured in
both vials and ampoules.
Patheon provides manufacturing services for a broad range of products in
many dosage forms and packaging formats in accordance with client
specifications. Depending on the particular client, Patheon may be responsible
for most or all aspects of the manufacturing and packaging process, from
sourcing raw materials and packaging components to delivering the finished
product in consumer-ready form to the client. Typically, Patheon's clients
supply the active pharmaceutical ingredients ("API") used in the production
process.
The pharmaceutical development services ("PDS") provided by Patheon
include most of the pharmaceutical development services typically required by
companies conducting clinical trials and preparing for full-scale commercial
production of a new drug.
At July 31, 2005, there were a total of 137 client projects in Patheon's
PDS pipeline, including seven drug candidates at the New Drug Application
("NDA") stage.
Vision and Strategy
Patheon's vision is to be the pre-eminent provider of pharmaceutical
manufacturing and development services across several dosage forms (solid,
semi-solid, liquid, powder and sterile/injectable). To achieve its goal,
Patheon has focused on being the preferred manufacturing and pharmaceutical
development services partner to the pharmaceutical industry. The Company
intends to use its position as a comprehensive provider of commercial
manufacturing services to establish and maintain long-term relationships with
clients on a global basis.
Key Performance Drivers
In Patheon's 2004 Annual Report, several key performance drivers were
identified for the Company: (i) increasing the percentage of overall revenues
derived from higher-margin Rx commercial manufacturing and pharmaceutical
development services; (ii) improving capacity utilization at the Company's
sites, which have a largely fixed-cost base in the short term; and (iii)
mitigating the impact of changes in the foreign exchange trading relationship
between the Canadian and U.S. dollar, since the Company's contracts in North
America are primarily in U.S. dollars, but the operating expenses of its six
Canadian sites are primarily in Canadian dollars. An update on our interim
performance relating to these key measures is provided in the section below
entitled "Results of Operations".
Acquisition of MOVA in the first quarter of 2005
On December 23, 2004, the Company completed the acquisition of MOVA
Pharmaceutical Corporation and MOVA Investments, Inc. (collectively "MOVA"), a
leading U.S. prescription pharmaceutical contract manufacturer located in
Puerto Rico, U.S.A.
The purchase price for the shares of MOVA was based on an enterprise
value for MOVA at closing of $350,000,000. The Company issued 12,684,866
common shares to the shareholders of MOVA in satisfaction of $81,500,000 of
the purchase price. The Company assumed approximately $133,300,000 in debt and
related costs, and paid $135,200,000 in cash at closing.
The agreement also provided for two earn-out arrangements relating to
MOVA's operating results for two specific periods. The maximum amounts for the
first and second earn-outs were $65 million and $26 million, respectively. The
Company placed into escrow $87.8 million to support potential payments under
the earn-out arrangements. An agreement was reached with the former MOVA
shareholders to pay the full amount of the first earn- out arrangement and $65
million was disbursed from escrow on June 23, 2005. It was determined that no
amount was payable under the second earn-out and the remaining funds held in
escrow were released to the Company and applied to reduce debt.
The acquisition has been accounted for using the purchase method and the
accompanying consolidated financial statements include the results of
operations from the date of purchase. The purchase price was allocated in the
accounts based on the estimated fair value of the assets acquired as follows:
-----------
$
-----------
Current assets 62,305
Capital assets 142,001
Other long term assets 1,719
Intangible assets 116,274
Goodwill 158,875
Current liabilities (33,887)
Deferred revenues (7,096)
Future tax liabilities (4,041)
-----------
Net assets acquired before assumed debt 436,150
Less: debt assumed (133,333)
-----------
Net assets acquired 302,817
-----------
-----------
Intangible assets which represent the value assigned to client contracts
are being amortized on a straight-line basis over nine years.
The purchase price and related allocations for this acquisition are
preliminary. Adjustments to the purchase price and related preliminary
allocations may occur as a result of obtaining more information regarding
asset valuations, liabilities assumed, purchase price adjustments pursuant to
the purchase agreement and revisions of preliminary estimates of fair value
made at the date of purchase.
The purchase price consideration was as follows:
-----------
$
-----------
Cash consideration 211,237
Transaction costs 3,284
-----------
Total cash consideration 214,521
Value of 12,684,866 common shares issued to
shareholders of MOVA 88,296
-----------
Total consideration 302,817
-----------
-----------
In accordance with generally accepted accounting principles, the value of
the 12,684,866 common shares was determined based on the average market price
of the Company's common shares for the two trading days prior to the
announcement of the transaction and the two trading days following the
announcement.
Results of Operations
Three Months Ended July 31, 2005 Compared with Three Months Ended
July 31, 2004
The results for the three-month period ended July 31, 2005 include the
operations of MOVA for three months, while the results of the comparative
period do not.
Revenues by Geographic Region and Service Activity
Three months ended Nine months ended
July 31, July 31,
% %
2005 2004 Change 2005 2004 Change
---------------------------------------------------
North America
-------------
Commercial
Manufacturing
Prescription 79,937 36,332 120% 234,193 105,922 121%
Over-the-counter 24,922 25,626 -3% 79,917 73,348 9%
---------------------------------------------------
-
104,859 61,958 69% 314,110 179,270 75%
Development
Services 17,074 12,872 33% 51,851 38,869 33%
---------------------------------------------------
121,933 74,830 63% 365,961 218,139 68%
---------------------------------------------------
Europe
------
Commercial
Manufacturing
Prescription 51,526 38,110 35% 136,224 119,939 14%
Over-the-counter 625 369 69% 1,561 1,170 33%
---------------------------------------------------
52,151 38,479 36% 137,785 121,109 14%
Development
Services 4,306 3,531 22% 12,679 8,190 55%
---------------------------------------------------
56,457 42,010 34% 150,464 129,299 16%
---------------------------------------------------
TOTAL
-----
Commercial
Manufacturing
Prescription 131,463 74,442 77% 370,417 225,861 64%
Over-the-counter 25,547 25,995 -2% 81,478 74,518 9%
---------------------------------------------------
157,010 100,437 56% 451,895 300,379 50%
Development
Services 21,380 16,403 30% 64,530 47,059 37%
---------------------------------------------------
CONSOLIDATED
REVENUES 178,390 116,840 53% 516,425 347,438 49%
---------------------------------------------------
---------------------------------------------------
Revenues
Consolidated revenues for the three-month period ended July 31, 2005
increased 53% or $61.6 million to $178.4 million from $116.8 million in the
same period in 2004. In the third quarter, growth came from prescription (Rx)
manufacturing and pharmaceutical development services (PDS) in both North
America and Europe. On a consolidated basis, commercial manufacturing revenues
grew 56%, with Rx manufacturing up 77%, offset somewhat by a 2% decline in
over- the-counter (OTC) manufacturing. PDS revenues were up 30% compared with
the same period in 2004.
Internal growth, or new business from existing sites, was $22.2 million,
or 19%, in the third quarter of 2005, 10% in North America and 34% in Europe.
Internal growth in North America was attributable principally to Rx
manufacturing and PDS services, which were up $6.2 million or 17%, and $2.2
million or 17%, respectively, compared with the same period in 2004. In
Europe, growth was also attributable principally to Rx manufacturing and PDS
services, which were up $13.4 million, or 35% and $0.8 million, or 22%,
respectively, compared with the same period in 2004. Internal growth of Rx
revenues in Europe of 35% in the third quarter of 2005, compared with the same
period in the prior year, was particularly strong, reflecting a significant
contribution from the Swindon, U.K. and Ferentino, Italy operations. In the
third quarter of 2005, the Company received approval from the Italian Ministry
of Health for the manufacture of large-volume parenterals at the Ferentino,
Italy site and manufacturing commenced in the quarter. On a constant exchange
rate (CER) basis to prior year, internal growth in Europe was 34% in the third
quarter of 2005, the same as reported.
Prescription manufacturing and development services represented 86% of
revenues, compared with 78% for the comparable period in 2004, a result of
internal growth in Rx and PDS services and strategic growth from MOVA, where
commercial services are all Rx. OTC revenues decreased 2% in the third
quarter, as compared with the same period a year ago, a result of lower OTC
volumes in North America. PDS revenues increased 30% in the third quarter,
reflecting continuing momentum at PDS sites in North America and Europe. PDS
third quarter revenue growth was 33% in North America and 22% in Europe, as
compared with the same period a year ago. Growth in PDS revenues reflects the
continuing favourable financing environment for drug development as well as
Patheon's enhanced reputation in the marketplace for the Company's ability to
provide formulation development services and commercialization of newly
approved products for its clients.
Geographically, North American revenue growth was $47.1 million or 63%
over the same period in the prior year. Of the revenue increase, $39.4 million
was strategic growth related to the acquisition of the MOVA operations. MOVA
revenues in the third quarter were impacted principally by the shortage of a
client-supplied active pharmaceutical ingredient ("API") on a large-volume
product and an adjustment in production requirements for a new product
launched in 2004. Net internal growth was $7.7 million, reflecting growth in
both Rx and PDS services. In North America, Rx revenues were driven by new
product launches at the Toronto high-potency site. North American PDS revenues
continued the growth trend experienced through 2005.
Revenues from sites in North America represented 68% of total revenues in
the third quarter of 2005, compared with 64% in the same period in 2004. This
reflects the inclusion of revenues related to the MOVA operations and growth
in Rx and PDS service activities from the other operations in North America.
In Europe, revenues for the third quarter of 2005 were 34% higher than
the same period of 2004. European currencies had nominal changes against the
U.S. dollar in the third quarter of fiscal 2005 compared with the prior year.
The euro strengthened approximately 1% and the British sterling weakened
approximately 1% against the U.S. dollar, increasing reported revenues by
approximately $0.3 million, with no material impact on net earnings or
earnings per share, on a constant exchange rate (CER) basis. The
year-over-year increase in revenues is due to improved performance at each
of the four European sites, led by the Swindon, U.K. operations.
Operating Expenses
Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the third quarter of 2005, operating
expenses were $152.6 million, compared with $105.8 million in the same period
a year ago, an increase of 44%. Operating expenses as a percentage of revenues
were 85.5%, compared with 90.6% in the prior year. Excluding the impact of the
MOVA operations, operating expenses as a percentage of revenues were 85.5%
compared with 90.6% in the same period a year ago. Excluding the impact of
repositioning expenses, operating expenses as a percentage of revenues in the
third quarter of 2004 were 88.7%.
EBITDA and EBITDA Margin
On a consolidated basis in the third quarter of 2005, EBITDA,
representing earnings before interest, income taxes, and depreciation and
amortization was $25.8 million, an increase of $14.8 million, or 134%, from
the comparable period in 2004. As a percentage of consolidated revenues, the
EBITDA margin was 14.5% in the three-month period, compared with 9.4% in the
same period a year ago. The comparable EBITDA margin in the prior year
excluding the U.K. repositioning costs was 11.3%. While in prior quarters of
2005, MOVA had higher EBITDA margins than other operations in the Company's
network, third quarter 2005 EBITDA margins of MOVA were comparable with the
other operations. MOVA EBITDA margins were lower in the third quarter of 2005
due to reduced capacity utilization. However, combined EBITDA margins for the
other sites in the Company's network showed year-over-year sequential
improvement. This was largely due to higher volumes of higher- margin products
manufactured at the Italian sites, significantly improved financial
performance at the Swindon, U.K. operations and new product launches and
volume increases at the Toronto high-potency site. Year-over-year growth in
EBITDA margins for the third quarter was also favourably impacted by the
continued growth in PDS revenues.
Depreciation Expense
Depreciation expense was $8.9 million in the third quarter of 2005,
compared with $5.7 million in the third quarter of 2004, an increase of $3.2
million, or 54%. Of the increase, $2.6 million is attributable to additional
amounts relating to depreciation of the MOVA assets, $0.3 million is
attributable to the effect of translation to U.S. dollars of depreciation
related to Canadian and European sites, and the remainder principally related
to the capital programs at the Italian sites and capital programs in North
America, principally at the Toronto, Canada, and Cincinnati, U.S.A. sites.
Depreciation expense also includes the amortization of deferred pre-operating
costs, although there was no significant change on a year-over-year basis.
Amortization of Deferred Financing Costs
Amortization of deferred financing costs in the third quarter of 2005 was
$1.4 million, comparable to the amount recorded in the previous quarter. No
amounts were recorded for the same period in the prior year. There were no
amounts of a non-recurring nature in the third quarter.
Amortization of Intangible Assets
The amortization of intangible assets relates to the acquisition of the
MOVA operations. Intangible assets, which represent the value assigned to
client contracts, are being amortized on a straight-line basis over nine
years. The quarterly amortization amount on this basis is approximately $3.2
million.
Interest Expense
Interest expense for the third quarter of 2005 was $4.8 million,
comparable to the second quarter of 2005, but is an increase of $3.4 million
over the same period in the prior year. Approximately $2.9 million of the year-
over-year increase is related to new debt associated with the acquisition of
the MOVA operations in December 2004.
Earnings Before Income Taxes
Earnings before income taxes, increased 95% to $7.6 million in the third
quarter of 2005, from $3.9 million in the same period a year ago. The increase
is attributed to increased volumes from certain North American operations and
the U.K. operations, as compared with the same period in the prior year. This
was offset by increased depreciation and amortization charges in the third
quarter of 2005, related to the MOVA acquisition, and increased depreciation
and interest expense in North America and Europe, related to ongoing capital
and growth support programs.
Income Taxes
The effective income tax rate in the third quarter of 2005 was 54.4%
versus 48.8% for the same period a year ago. The effective rate in the prior
year reflected the impact of losses incurred in the U.K. which were recorded
at 30%, a rate which is lower than other Patheon operations in 2004. The
effective tax rate of 54.4% in the third quarter of 2005 reflects a reduction
arising from the improved operating performance in the U.K. but this was
offset by the inclusion of the MOVA operations, currently at the lowest tax
rate in the Patheon group.
Net Earnings and Earnings Per Share
Net earnings for the third quarter of 2005 were $3.5 million, compared
with $2.0 million in the same period last year, an increase of $1.5 million,
or 74%. However, earnings per share of 3.5 cents were lower than the 3.9 cents
achieved a year earlier because of reduced capacity utilization at the MOVA
sites and an increase in the average number of shares outstanding as a result
of the acquisition of the MOVA operations, as compared with the same period a
year ago. Net earnings before repositioning expenses were $3.5 million in the
third quarter of 2004, comparable to the third quarter of 2005. Earnings
before repositioning expenses in the third quarter of 2004 were 6.8 cents,
based on a lower number of average shares outstanding for the period due to
the issue of common shares in fiscal 2005.
The average number of shares outstanding during the three-month period,
determined on the basic and diluted bases, increased 80% and 79% respectively.
The increase is the result of shares issued in connection with the acquisition
of MOVA, as described in notes 3 and 4 of the financial statements herein.
Diluted earnings per share were 3.4 cents compared with 3.9 cents in the
third quarter of 2004, a decrease of 13%. Dilution arises solely from options
issued under the Company's stock option plan.
Nine Months Ended July 31, 2005 Compared with Nine Months Ended
July 31, 2004
The results for the nine-month period ended July 31, 2005 include the
operations of MOVA since the date of acquisition on December 23, 2004, while
the results of the comparative period do not.
Revenues
Consolidated revenues for the nine-month period ended July 31, 2005
increased 49% or $169.0 million to $516.4 million from $347.4 million in the
same period in 2004. In the nine-month period, all service activities
contributed to the growth. On a consolidated basis, commercial manufacturing
revenues grew 50%, with prescription (Rx) manufacturing up 64% and over-the-
counter (OTC) manufacturing up 9% and pharmaceutical development services
(PDS) revenues up 37%.
Internal growth, or new business from existing sites, was $60.6 million,
or 17%, in the nine-month period of 2005, 18% in North America and 16% in
Europe. All service activities contributed to the strong internal growth in
North America. In Europe, growth was attributable principally to Rx
manufacturing and PDS services, which were up $16.3 million, or 14% and $4.5
million, or 55%, respectively, compared with the same period in 2004.
Prescription manufacturing and development services represented 84% of
revenues, compared with 79% for the comparable period in 2004, a result of
internal growth in Rx and PDS services and strategic growth from MOVA, where
commercial services are all Rx.
OTC revenues increased 9% in the first nine months of 2005, as compared
with the same period a year ago. While the Company reported double-digit
growth in OTC revenues in North America in the first and second quarters of
2005, OTC revenues declined 3% in the third quarter of 2005, as compared with
the same period a year ago. This segment of the pharmaceutical market is
highly competitive, price-sensitive and subject to volatility in consumer
demand.
PDS revenues increased 37% in the nine-month period, reflecting
continuing momentum at PDS sites in North America and Europe. PDS nine-month
revenue growth was 33% in North America and 55% in Europe, as compared with
the same period a year ago. Growth in PDS revenues reflects the continuing
favourable financing environment for drug development as well as the Company's
enhanced reputation in the marketplace to provide formulation development
services and commercialization of newly approved products for its clients.
Geographically, North American revenue growth was $147.8 million or 68%
over the same period in the prior year. Of the revenue increase, $108.4
million was strategic growth related to the acquisition of the MOVA
operations. Net internal growth was $39.4 million, or 18%, reflecting strong
growth in Rx manufacturing services, principally from the Toronto high-
potency operations. In Europe, significant year-over-year increases in Rx
internal growth revenues came principally from the Swindon, U.K. and the
Italian operations. Strong growth in PDS was reported at the Canadian,
European and Cincinnati sites.
Revenues from sites in North America represented 71% of total revenues in
the first nine months of 2005, compared with 63% in the same period in 2004.
This reflects the inclusion of revenues related to the MOVA operations and
growth in all service activities from the other operations in North America.
In Europe, revenues for the first nine months of 2005 were 16% higher
than the same period of 2004. European currencies remained strong against the
U.S. dollar in the first nine months of fiscal 2005 compared with the prior
year. The euro strengthened approximately 5% and the British sterling
strengthened approximately 3% against the U.S. dollar, increasing reported
revenues by approximately $6.1 million. Had European currencies remained
constant to the rates of the prior year, European revenues would have been 12%
higher than the same period in 2004. Net earnings for the first nine months of
2005 would have been higher by approximately 0.4 cents per share, on a
constant exchange rate (CER) basis.
Operating Expenses
Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the first nine months of 2005,
operating expenses were $444.7 million, compared with $312.8 million in the
same period a year ago, an increase of 42%. Operating expenses as a percentage
of revenues were 86.1%, compared with 90.0% in the prior year. Excluding the
impact of repositioning expenses, operating expenses as a percentage of
revenues were 89.4% in the first nine months of 2004. Excluding the impact of
the MOVA operations, operating expenses as a percentage of revenues were 88.5%
in the first nine months of 2005.
EBITDA and EBITDA Margin
On a consolidated basis in the first nine months of 2005, EBITDA,
representing earnings before interest, income taxes, and depreciation and
amortization was $71.8 million, an increase of $37.1 million, or 107%, from
the comparable period in 2004. As a percentage of consolidated revenues,
EBITDA was 13.9% in the nine-month period, compared with 10.0% in the same
period a year ago. Excluding the impact of repositioning expenses, EBITDA as a
percentage of consolidated revenue was 10.6% in the first nine months of 2004.
The growth in EBITDA is attributed principally to the contribution of the MOVA
business and increases in Rx and PDS services in North America and Europe.
Depreciation Expense
Depreciation expense was $25.5 million in the first nine months of 2005,
compared with $16.8 million in the same period of 2004, an increase of $8.7
million, or 52%. Of the increase, $6.3 million is attributable to additional
amounts relating to depreciation of the MOVA assets, $1.3 million is
attributable to the effect of translation to U.S. dollars of depreciation
related to Canadian and European sites, and the remainder principally related
to the capital programs at the Italian sites and capital programs in North
America, principally at the Toronto, Canada, and Cincinnati, U.S.A. sites.
Depreciation expense also includes the amortization of deferred pre-operating
costs.
Amortization of Deferred Financing Costs
Amortization of deferred financing costs in the first nine months of 2005
was $5.5 million. No amounts were recorded for the same period in the prior
year. Of the increase, $2.0 million was recorded in the first quarter of 2005
and is of a non-recurring nature. The amortization in the second and third
quarters of 2005 do not include amounts of a non-recurring nature.
Amortization of Intangible Assets
The amortization of intangible assets of $7.7 million in the first nine
months of 2005 relates to the acquisition of the MOVA operations in December
2004. Intangible assets, which represent the value assigned to client
contracts, are being amortized on a straight-line basis over nine years.
Interest Expense
Interest expense for the first nine months of 2005 was $11.8 million
compared with $3.8 million in the same period a year ago, an increase of $8.0
million. Approximately $6.5 million of the year-over-year increase is related
to new debt associated with the acquisition of the MOVA operations in December
2004. The remainder of the year-over-year increase is principally related to
increased spending to finance the capital programs in North America and
Europe.
Earnings Before Income Taxes
Earnings before income taxes, increased 51% to $21.1 million in the first
nine months of 2005, from $14.0 million in the same period a year ago. The
increase is attributed to the inclusion of the results of the MOVA operations,
increased volumes from certain North American operations and the European
operations, as compared with the same period in the prior year. This was
offset by increased depreciation and amortization charges, related to the MOVA
acquisition, and increased depreciation and interest expense in North America
and Europe, related to ongoing capital and growth support programs.
Income Taxes
The effective income tax rate for the nine months ended July 31, 2005 was
37.4% versus 45.1% for the same period a year ago. The effective tax rate in
the prior period was significantly impacted by the losses incurred at the U.K.
operations, which were at 30%, a rate lower than the other Patheon operations
in 2004. The lower effective tax rate for the nine-month period in 2005
reflects the positive impact of the improved financial performance of the U.K.
operations as well as the inclusion of earnings from the MOVA operations as of
December 23, 2004. The effective tax rate for the MOVA operations in Puerto
Rico, U.S.A. is approximately 3%. As a result, the amounts of earnings from
operations in Puerto Rico, relative to earnings of the Company's earnings
outside of Puerto Rico, can significantly impact the consolidated effective
tax rate.
Net Earnings and Earnings Per Share
Net earnings for the nine months ended July 31, 2005 were $13.2 million,
compared with $7.7 million in the same period last year, an increase of $5.5
million, or 72%. Basic earnings per share for the first nine months of 2005
were 15.6 cents compared with 14.9 cents in the same period of 2004, an
increase of 5%. Excluding the impact of repositioning expenses, basic earnings
per share in the first nine months of 2004 were 17.8 cents. Year-to-date
results were impacted positively by improved operating performance,
principally at the Toronto high-potency site, the European operations and the
year-over-year growth in PDS. The MOVA operations were not accretive to
earnings in the nine-month period ended July 31, 2005 as a result of issues
with two key products.
The average number of shares outstanding during the nine-month period,
determined on the basic and diluted bases, increased 65% and 64%,
respectively. The increase is the result of shares issued in connection with
the acquisition of MOVA, as described in notes 3 and 4 of the financial
statements herein.
Diluted earnings per share were 15.5 cents compared with 14.8 cents in
the first nine months of 2004, an increase of 5%. Dilution arises solely from
options issued under the Company's stock option plan.
Seasonal Variability of Results
Typically, Patheon's manufacturing and PDS revenues are lower in the
first fiscal quarter. While commercial revenues in Europe followed this
pattern, this was not the case for the European PDS revenues or for North
American PDS and commercial volumes. This is principally attributable to
higher-than-anticipated commercial volumes at the Canadian sites related to
new business and product launches, and continuing strong demand for PDS
related to existing contracts in the first quarter. This trend continued in
the second and third quarters with the inclusion of full quarters of MOVA
operations, strong commercial demand in Europe and strong sequential demand
for PDS principally driven from the MOVA and U.K. operations.
Liquidity and Capital Resources
Summary of Cash Flows
The following table summarizes the Company's cash flows for the periods
indicated:
Three months Nine months
ended July 31, ended July 31,
2005 2004 2005 2004
------------------- ------------------
-
$ $ $ $
------------------- ------------------
Net earnings 3,455 1,990 13,242 7,681
Depreciation and amortization 13,463 5,743 38,821 16,814
Future income taxes 389 (469) 671 1,655
Employee future benefits 586 664 1,395 1,807
Equipment write-down (note 13) - 750 - 750
Stock-based compensation 366 433 1,209 928
Amortization of deferred
revenues (280) - (618) -
Other 165 - 165 -
Working capital 2,831 (8,370) (10,314) (9,831)
------------------- ------------------
Cash provided by operating
activities 20,975 741 44,571 19,804
Cash provided by (used in)
financing activities (23,449) 5,905 236,753 19,056
Cash provided by (used in)
investing activities 5,274 (13,656) (265,011) (44,433)
Other (12) (378) (4,973) (181)
------------------- ------------------
Net increase (decrease) in
cash and cash equivalents 2,788 (7,388) 11,340 (5,754)
------------------- ------------------
------------------- ------------------
Note reference is to the unaudited consolidated financial statements for
the three-month and nine-month period ended July 31, 2005.
On a year-to-date consolidated basis, the free cash flow generated in the
first quarter of 2005 was offset somewhat by higher cash needs in the second
and third quarters to finance working capital and capital spending programs.
Free cash flow is defined as cash provided by operating activities in excess
of additions to capital assets in the period. Free cash flow is a non-GAAP
measure. Please refer to the section describing the use of non-GAAP measures
in this MD&A.
Generation of cash from working capital was $2.8 million in the third
quarter of 2005, compared with the requirement to fund working capital on a
year-to-date basis of $10.3 million in 2005. This was principally a result of
the phasing of manufacturing and related client billings and the impact of the
MOVA operations for the first full quarter.
Cash Provided by Operating Activities
Cash provided by operating activities increased by $20.2 million to $21.0
million in the third quarter of 2005, compared with the same period a year
ago. Of the increase, $9.0 million related to the year-over-year increase in
cash provided from operations and the remainder from improvements in working
capital management in the quarter, principally at the MOVA operations.
For the nine-month period, cash provided by operating activities
increased by $24.8 million, principally all of which related to the increase
in cash provided from operations. The Company will continue its focus on
working capital management in 2005.
Cash Provided by Investing Activities
Cash provided by investing activities for the third quarter of 2005 was
$5.3 million, compared with a use of $13.7 million in the same period of 2004.
The increase is principally related to the release of funds held in escrow in
connection with the acquisition of the MOVA operations relating to funds held
for the second earn-out that was not payable.
Cash used in investing activities for the nine months ended July 31, 2005
was $265.0 million, compared with $44.4 million in the same period of 2004.
The year-over-year increase is principally related to the MOVA acquisition on
December 23, 2004. A summary is as follows:
Three months Nine months
ended July 31, ended July 31,
2005 2004 2005 2004
------------------- ------------------
$ $ $ $
------------------- ------------------
Additions to capital assets
Sustaining 4,998 2,690 9,328 8,041
Project-related 7,557 9,454 29,553 34,880
------------------- ------------------
Total additions to capital assets 12,555 12,144 38,881 42,921
Acquisition of MOVA
Pharmaceutical Corporation
(note 3) 69,976 - 214,521 -
Decrease in escrow cash related
to MOVA acquisition (note 3) (87,825) - - -
Redemption of certificate of
deposit (391) - (391) -
Increase in deferred pre-
operating and financing costs 411 1,512 12,000 1,512
------------------- ------------------
Cash used in (provided by)
investing activities (5,274) 13,656 265,011 44,433
------------------- ------------------
------------------- ------------------
Note reference is to the unaudited consolidated financial statements for
the three-month and nine-month period ended July 31, 2005.
Cash Provided by Financing Activities
The principal financing activity for the nine months ended July 31, 2005
occurred in the first quarter of 2005, and was the completion of the common
share offering. Proceeds from the offering were $199.2 million, before costs,
and $190.3 million after costs. Proceeds were used to finance a portion of the
purchase price of MOVA of $350.0 million and to finance, in escrow,
approximately 90% of the maximum amount of $91.0 million potentially payable
under the earn-out agreements. The Company placed into escrow $87.8 million to
support potential payments under the earn-out arrangements. An agreement was
reached with the former MOVA shareholders to pay the full amount of the first
earn-out arrangement and $65 million was disbursed from escrow on June 23,
2005. It was determined that no amount was payable under the second earn-out
and the remaining funds held in escrow were released to the Company and
applied to reduce debt. A summary is as follows:
Three months Nine months
ended July 31, ended July 31,
2005 2004 2005 2004
------------------- ------------------
$ $ $ $
------------------- ------------------
Increase (decrease) in bank
indebtedness (5,888) (729) (7,731) 3,719
Increase in term loans 64,179 47,033 295,090 61,303
Repayment of long-term debt and
other long-term liabilities (90,011) (40,421) (249,171) (45,988)
Increase in deferred revenues
(note 12) 8,271 - 8,271 -
Proceeds on issue of common
shares before costs - 22 199,241 22
Share issue costs - - (8,947) -
------------------- ------------------
Cash provided by (used in)
financing activities (23,449) 5,905 236,753 19,056
------------------- ------------------
------------------- ------------------
Note reference is to the unaudited consolidated financial statements for
the three-month and nine-month period ended July 31, 2005.
Financing Arrangements and Ratios
At July 31, 2005, the Company's consolidated ratio of interest-bearing
long-term debt (including current portion) to shareholders' equity was 57.8%
compared with 64.6% at April 30, 2005 and 56.1% at October 31, 2004. At July
31, 2005, the Company's consolidated ratio of interest-bearing debt (including
current portion and bank indebtedness) to shareholders' equity was 60.3%,
compared with 68.5% at April 30, 2005 and 65.9% at the end of the 2004 fiscal
year. The reduction was principally due to the release of funds held in escrow
which were applied against the bridge facility.
The Certificate of deposit of $4,824,000 and $4,086,000 of the amount
reported as cash and cash equivalents are restricted cash and are held in
support of certain debt agreements of MOVA.
Certain of the loan agreements which were assumed by the Company on
closing of the acquisition of MOVA Pharmaceutical Corporation require MOVA to
maintain certain financial covenants, as measured quarterly on a calendar-
year basis. As of December 31, 2004 and June 30, 2005, MOVA's compliance
reporting dates, MOVA was not in compliance with certain of the financial
covenants. The lending institutions have waived their rights under the terms
of the loan agreements for the non-compliance of these covenants for a period
of time up to November 1, 2006 and any cross-default provisions of the
$169,000,000 credit facility, referred to above, have also been remedied.
Therefore, no change has been made to assumptions on long-term debt as
presented in the accompanying balance sheet.
On December 23, 2004 the Company completed a financing agreement for a
new $169,000,000 committed facility, comprising a three-year revolving credit
facility of up to $55,000,000 and a 12-month bridge facility of $114,000,000.
This bridge facility is intended to be refinanced by a term loan within 12
months of the completion date. At the signing of the financing agreement,
$116,000,000 was drawn under these facilities in partial payment of the cash
portion of the purchase price of MOVA and related transaction costs, and to
refinance substantially all of the Company's existing North American debt of
approximately $63,000,000. At July 31, 2005, the amount drawn under this
bridge facility was $81,500,000 compared with $99,700,000 at April 30, 2005.
Until the bridge facility is refinanced, the amount outstanding is shown as a
current liability.
With the acquisition of MOVA, the Company assumed $133.3 million of debt
in the form of bank debt and capital lease obligations secured by the assets
of MOVA.
Adequacy of Financial Resources
The Company believes that its financial resources are sufficient to fund
projected capital expenditures and debt service requirements in the normal
course of business. The Company is in the process of refinancing the bridge
facility of $81.5 million, referred to above, to a term loan facility.
Critical Accounting Policies and Estimates
General
Patheon's significant accounting policies are described in Note 1 to the
2004 consolidated financial statements. The most critical of these policies
are those related to revenue recognition, goodwill, income taxes and employee
future benefits (Notes 1, 12 and 13 of the 2004 audited financial statements).
The preparation of the consolidated financial statements requires
management to make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenues and expenses. These estimates and assumptions
are based upon management's historical experience and are believed by
management to be reasonable under the circumstances. Such estimates and
assumptions are evaluated on an ongoing basis and form the basis for making
judgments about the carrying values of assets and liabilities that are not
readily apparent from other sources. Actual results could differ significantly
from these estimates.
The Company's Critical Accounting Policies have been reviewed and
discussed with the Company's Audit Committee.
Revenue Recognition
The Company recognizes revenue for its commercial manufacturing and
pharmaceutical development services when services are completed in accordance
with specific agreements with its clients and all costs connected with
providing these services have been incurred, price is fixed or determinable
and collectibility is reasonably assured.
The Company does not receive any fees on signing of contracts. In the
case of pharmaceutical development services, revenue is recognized on the
achievement of specific milestones. In the case of commercial manufacturing
services, revenue is recognized when services are complete and the product has
met rigourous quality assurance testing.
Valuation of Goodwill
The Company evaluates goodwill for impairment at least annually. If the
carrying value of the reporting unit exceeds the reporting unit's fair value,
any excess represents an impairment loss.
The goodwill shown on the financial statements for the period ended July
31, 2005 was $162.9 million and relates to the acquisition in 2000 of the
remaining shares of Global Pharm Inc., which now operates as Toronto York
Mills Operations, and from the acquisition of MOVA Pharmaceutical Corporation
on December 23, 2004. As at July 31, 2005, goodwill shown on the financial
statements relating to the MOVA acquisition was $160.1 million and goodwill
shown relating to Toronto York Mills acquisition was $2.8 million.
Income Taxes
In accordance with Canadian GAAP, the Company uses the liability method
of accounting for future income taxes and provides for future income taxes for
significant temporary timing differences.
Preparation of the consolidated financial statements requires an estimate
of income taxes in each of the jurisdictions in which the Company operates.
The process involves an estimate of the Company's current tax exposure and an
assessment of temporary differences resulting from differing treatment of
items such as depreciation and amortization for tax and accounting purposes.
These differences result in future tax assets and liabilities and are
reflected in the consolidated balance sheet.
Future tax assets of $19.7 million have been recorded at July 31, 2005.
This is comprised primarily of accounting provisions related to pension and
post-retirement benefits not currently deductible for tax purposes, the tax
benefit of net operating loss carryforwards related to the UK operations and
share issue costs associated with the offering in relation to the acquisition
of the MOVA. The Company evaluates quarterly the ability to realize its future
tax assets. The factors used to assess the likelihood of realization are the
Company's forecast of future taxable income and available tax planning
strategies that could be implemented to realize the future tax assets. The
Company has available to it tax planning strategies to realize future tax
assets in order to avoid the potential loss of benefits.
Future tax liabilities of $33.7 million have been recorded at July 31,
2005. This liability is comprised primarily of tax depreciation in excess of
book depreciation.
The Company's tax filings are subject to audit by taxation authorities.
Although management believes that it has adequately provided for income taxes
based on the information available, the outcome of audits cannot be known with
certainty and the potential impact on the financial statements is not
determinable.
Employee Future Benefits
The Company provides pensions and post-retirement benefits, including
medical benefits and dental care. The determination of the obligation and
expense for defined benefit pensions and post-retirement benefits is dependent
on the selection of certain assumptions used by actuaries in calculating such
amounts. Those assumptions are disclosed in Note 13 to the Company's 2004
audited consolidated financial statements.
Risk Management
The following are updates to certain of the risks and uncertainties
described in the Management's Discussion and Analysis (MD&A) section of
Patheon's 2004 Annual Report, available on SEDAR (www.sedar.com) or on
Patheon's web site (www.patheon.com).
Foreign Currency
The Company's business activities are conducted in several currencies -
Canadian dollars and U.S. dollars for the Canadian operations, U.S. dollars
for the U.S. operations and euros and British sterling for the European
operations.
Since the European and U.S. operations conduct business principally in
their respective local currencies, the exposure to foreign currency gains and
losses is not significant. However, the Company's Canadian operations
negotiate sales contracts for payment in both U.S. and Canadian dollars, and
materials and equipment are purchased in both U.S. and Canadian dollars. The
majority of its non-material costs (including payroll, facilities' costs and
costs of locally sourced supplies and inventory) are denominated in Canadian
dollars. Approximately 65% to 75% of revenues of the Canadian operations and
approximately 15% to 25% of its operating expenses are transacted in U.S.
dollars. As a result, the Company may experience trading and translation gains
or losses because of volatility in the exchange rate between the Canadian and
U.S. dollar.
To mitigate this risk, the Company maintains net monetary asset and/or
liability balances in foreign currencies and engages in foreign currency
hedging activities using derivative financial instruments. The Company does
not purchase any derivative instruments for speculative purposes.
The Company has entered into forward exchange contracts to sell U.S
dollars and purchase Canadian dollars. The mark-to-market value of these
financial instruments as at July 31, 2005 was an unrealized gain of $0.3
million.
Translation gains and losses related to the carrying value of the
Company's foreign operations are deferred and included in the cumulative
translation account in shareholders' equity. At July 31, 2005, the balance in
the account was a $22.1 million gain compared with a $24.4 million gain at
October 31, 2004.
Additional Information
Share Capital
As of September 1, 2005, the Company had outstanding 92,845,688 common
shares and 1,029 Class I preferred shares.
Public Securities Filings
Other information about the Company, including the annual information
form and other disclosure documents, reports, statements or other information
that is filed with Canadian securities regulatory authorities can be accessed
through SEDAR at www.sedar.com.
Outlook
Looking ahead to the end of 2005 and beyond, the Company continues to
hone its business fundamentals and to capitalize on business opportunities
that will further enhance its global positioning in outsourced pharmaceutical
manufacturing.
The growing number of projects in the Company's PDS pipeline speaks to
the positive R&D spending trends and demand in both North America and Europe
for high-quality drug development services. At quarter end, the Company had a
total of 137 projects in its facilities, seven of which were at the NDA stage.
This compared with 109 projects just one year ago.
In North America, the demand for specialized Rx services, such as high-
potency capacity in Canada and our sustained-release capacity at Cincinnati,
continues to grow. However, the Company continues to be challenged to grow its
OTC business. This segment of the pharmaceutical market is highly competitive,
price-sensitive and subject to volatility in consumer demand.
The Company is encouraged by the all-round strong performance of its
European sites in the third quarter, both for Rx manufacturing and PDS
services. In addition to signing a number of contracts for our sterile and
cephalosporin capabilities, the Company has signed an important contract to
manufacture a new cephalosporin product for our Swindon site and two multi-
product contracts that will benefit our Italian and French sites. As reported
last quarter, the Company continues to be on track for profitability at
Swindon in 2006.
At MOVA, the Company has been faced with challenges that have impacted
operating results. The Company is pleased that the API shortage for a
significant product has improved, allowing higher production volumes to
resume. With regard to the new product launched in 2004, it is expected that
client requirements for the product will recover during the first part of
fiscal 2006. Both of these are large-volume products and, based on discussions
with clients, the Company anticipates that market demand for these products
will remain strong.
The Company is disappointed that as a result of issues with two key
products the MOVA operations will not be accretive to earnings per share in
2005 as originally expected. The Company has identified a number of new
opportunities to fill additional capacity at the MOVA sites, created by
changing client requirements for currently marketed products as well as by
anticipated volume declines of a product going off-patent in 2006. Based on
these new opportunities combined with the strategic benefits - additional Rx
manufacturing capabilities and expertise in a tax-advantaged location - that
MOVA has brought to the organization, the Company remains confident that MOVA
represents a significant opportunity for accretive growth.
No Auditor Review
Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an
auditor has not performed a review of the interim financial statements, they
must be accompanied by a notice indicating that the financial statements have
not been reviewed by an auditor.
The accompanying unaudited interim financial statements of the Company
have been prepared by and are the responsibility of management. The Company's
independent auditor has not performed a review of the financial statements for
the three-month and nine-month periods ended July 31, 2005 or for the
comparative periods ended July 31, 2004.
Forward-looking Information
This management's discussion and analysis of financial condition and
results of operations contains forward-looking statements with respect to the
Company, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by pharmaceutical companies (and in particular the Company's
clients), the impact of changes in pharmaceutical development and
manufacturing regulations and general economic and market factors (including
inflation and changes in laws) and other factors discussed in materials filed
with applicable securities regulatory authorities from time to time.
>>
%SEDAR: 00001700E